InfuSystem Holdings share price today

InfuSystem Holdings, Inc.'s share price was $13.15 at the close on 4 November 2026. That is 26.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between $8 and $14, and at that close it sat 86% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row.

Over the last 1 year the share price moved +127% while the S&P 500 moved +23%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

InfuSystem Holdings, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

InfuSystem Holdings is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

InfuSystem Holdings, Inc. earned $3.2 M of net profit in the Jun 2026 quarter, +24.3% on the same quarter a year earlier. Full-year FY25 profit was $6.6 M. Over 4 years profit has grown 47.0% a year on average. That is 8.7% of the quarter's revenue. The same quarter a year earlier earned $2.6 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

2 of the last 12 reported quarters were loss-making.

For the full year, FY25 profit was $6.6 M (+182.6% on the year before).

Why profit moved: revenue changed +2.6% on a year earlier and the margin moved +0.7 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +55.8% and revenue +2.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit.

InfuSystem Holdings, Inc. reported $36.9 M of revenue in the Jun 2026 quarter, +2.6% on the same quarter a year earlier. Over 4 years it has grown 8.8% a year on average. The last full year, FY25, came in at $143 M. The last four reported quarters add to $143 M.

Revenue is everything the company billed its customers in the period.

FY25 revenue was $143 M, +6.4% on the year before.

Recent pace: the last four quarters grew +2.5% on average, against 8.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +2.5%, against +5.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +68.4%, against +383.1% a year (rolling over).

InfuSystem Holdings, Inc.'s operating margin was 11.2% in the Jun 2026 quarter, 0.7 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 1.5% and 7.6%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between 1.5% and 7.6%, and FY25's 7.6% is the highest of them.

Why the margin moved: operating margin changed +0.7 percentage points on the year while gross margin changed +2.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 570% of InfuSystem Holdings, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $24.4 M of operating cash against $6.6 M of profit. After $8.7 M of spending on assets, $15.7 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

InfuSystem Holdings, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $37.6 M on assets over the last 3 years. Averaged over those years that is 8.7% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $37.6 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

InfuSystem Holdings, Inc.'s P/E is 32.8×, in the middle of its own history: higher than 61% of past readings. Its usual P/E (the middle reading) is 30.5×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +181.8% while the price moved +32.6%. Earnings did better than the price, which pulled the multiple down within its own range.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

InfuSystem Holdings, Inc.'s business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +1285.8% at its peak to +68.4%, but the business is still expanding, with ROCE rising at 13.5%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

InfuSystem Holdings, Inc. earned a ROE of 12% in FY25. That is up from a low of 0% in FY22. Its return on capital used (ROIC) is 1.5 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

It comes from a 4.6% net margin and 1.43× asset turnover (sales divided by assets).

Why the return is what it is (FY25): a 4.6% net margin × 1.43× asset turnover × 1.75× leverage (assets divided by equity) ≈ 11.5% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 9.6% − 11.1% = −1.5 percentage points. The 11.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The 9.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 8.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

InfuSystem Holdings, Inc. has total debt of $24.5 M against shareholder equity of $59.1 M as of Jun 2026, so its debt is 0.41× its equity. Year by year, that ratio went from 0.76 in FY21 to 0.43 in FY25. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

4.3% of InfuSystem Holdings, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 6.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For InfuSystem Holdings, Inc., the Z-score is 4.11. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 4.11 is well clear of the danger zone, so the balance sheet is not the risk here.

There is no score against its industry: InfuSystem Holdings, Inc. is not among the largest members shown in this industry comparison for Medical Devices.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

InfuSystem Holdings is the 68th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: ClearPoint Neuro, Inc., Treace Medical Concepts, Inc. and Quantum-Si incorporated. Just below it: Profound Medical Corp., Standard BioTools Inc. and TriSalus Life Sciences, Inc.

Medical Devices companies close in size

65. ClearPoint Neuro, Inc. $326 million
66. Treace Medical Concepts, Inc. $293 million
67. Quantum-Si incorporated $282 million
68. InfuSystem Holdings, Inc. $262 million
69. Profound Medical Corp. $259 million
70. Standard BioTools Inc. $242 million
71. TriSalus Life Sciences, Inc. $240 million

All 75 Medical Devices companies, largest first

Companies close in size in other industries

3245. OPAL Fuels Inc. $255 million · Utilities - Regulated Gas
3246. Profound Medical Corp. $255 million · Medical Devices
3247. InfuSystem Holdings, Inc. $255 million
3248. Jack in the Box Inc. $255 million · Restaurants
3249. Pure Cycle Corporation $254 million · Utilities - Regulated Water

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.